Statera Biopharma, Inc.

Good morning, ladies and gentlemen, and thank you for joining us for Satara Biopharma, Inc.' 's third quarter 2021 financial results conference call. Following the prepared remarks from the company, we will open the call for questions. I would now like to turn the call over to Satara's Executive Vice President of Investor Relations, Nicole Auschner. Ma'am, you may now begin.

Good afternoon, everyone, and thank you for joining the Satara Biopharma's 2021 third quarter financial results and corporate update call. Earlier this afternoon, Cetera Biopharma issued a press release detailing the financial results for the three and nine months ended September 30th, 2021, which we encourage listeners to read. The press release can be found in the investor section for CeteraBiopharma.com. Cetera also filed a 10-2 this afternoon, which is available on SEC.gov. Before beginning today's call, I would like to make the following statement. Today, we will be making certain forward-looking statements about operating metrics, future expectations, plans, events, and circumstances, including statements about our strategy, future operations, and the development and effectiveness of our investigational drug candidates, and our expectations regarding our capital allocation and cash resources. These statements are based on current expectations and you should not place undue reliance on these statements. Actual results may differ materially due to our risks and uncertainties, including those detailed in our most recent 10-K filing. CETERA disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise. With us on today's call is Michael K. Hanley, President and CEO of CETERA Biopharma, Inc., who will provide an update on Zotero's recent corporate and clinical achievements and the company's vision for the future. Mr. Peter Ehrenstam, Chief Financial Officer of Zotero Biopharma, who will discuss the company's financial results. And Dr. Tanya Markseka, Chief Operating Officer of Zotero, who will discuss the company's clinical program. I'd now like to turn the call over to our CEO, Michael Hanley. Michael, please go ahead.

Great. Thanks, Nicole. Thanks, everyone, for joining our conference this afternoon, including all of you joining for the first time. Today I'm speaking to you as CEO of Teterra BioPharma. Just three months ago, we were known as Cytocon. Through the reverse merger with Cleveland Biolabs and the acquisition of the drug development company MQuest Life Sciences, we emerged as a publicly traded company at the end of July, focused on developing the next generation of immune-modulating agents addressing autoimmune, infectious disease, cancer, and blood disorders. But a new company deserves a new name, reflective of the company's core focus and identity. On September 1, 2021, we formally rebranded Statera BioPharma with a new ticker symbol, STAB. Our name, Statera, is taken from the Latin word balance. And this, with our corporate tagline, Restoring Immune Health, we're chosen to reflect the strategic focus of the company and of our pipelines. Cetera is a clinical stage biopharmaceutical company at the forefront of developing the next generation of therapeutic agents focused on immune modulation and the restoration of immune homeostasis. In simple terms, we're driving the science which demonstrates that an overactive or an underactive immune system can drive disease progression. We are focused on developing drugs to restore and rebalance the immune system to address autoimmune, blood disorders, infectious disease, and cancer. With the recent merger, we have created one of the largest toll receptor platforms, and since then, we have not slowed down. Please advance to slide four. Our pipeline focus is initially targeting autoimmune disease with the STAT-201 program in pediatric Crohn's disease. We expect to expand into hematology with the STAT-600 program, or Intolamide, and oncology with the STAT-401 program in pancreatic cancer. Beyond our clinical programs, we're also working to develop new second-generation assets to further support our growth strategy and deepen our pipeline. We are already screening these first-round and second-generation immunomodulatory compounds, harnessing the tools and capabilities of our InQuest Life Science subsidiary to select those compounds most likely to succeed in preclinical and clinical trials. CITERA is also establishing new research alliances. In August, we finalized a five-year drug discovery agreement with the Hoya Institute of Immunology directed to research that will support the development of potential new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and some chronic inflammatory diseases. The research will harness the Terra's proprietary drug discovery and development platform technology. We are pleased to add this prestigious research center to the growing list of those involved in our development and clinical programs. Included on this list is Loma Linda, University Health, and Roswell Park Comprehensive Cancer Center in Buffalo, New York. Work is also underway to integrate the former Inquest Life Sciences and Cleveland Biolab to organizations, as well as its subsidiaries and joint ventures with Deterra. We're exploring opportunities to monetize non-core assets. In the meantime, we expect to achieve several clinical and corporate milestones over the next 12 to 18 months. Our ultimate goal is to change the way people think about immunotherapy. Statera has promising technology focused on delivering immune therapies that target toll-like immune receptors, a type of protein central to the immune response that plays a key role in fighting disease and restoring immune homeostasis. We believe Statera now has one of the largest platforms of toll-like receptors in the pharmaceutical industry, with our toll-like receptor 4, toll-like receptor 9 antagonists, and our toll-like receptor 5 agonists in Tolomid and GP532. We also plan to further strengthen the balance sheet to enable the growth and expansion of our pipeline. Our CFO, Peter Ernst then, will review our quarterly numbers and financing arrangements, including a credit facility and equity line and credit agreement. The company ended the third quarter with approximately $14.4 million in cash on hand and expects to strengthen our capital position by the end of the year to further grow our initiatives, fund business development plans, and advance development of our internal pipelines. With that as an intro, I'd like now to hand our call over to CFO Pierre Ehrenstam, who will discuss the third quarter of financial results.